Core Insights - Daxor Corporation has launched the ezBVA Lab program in partnership with a leading 1,000+ bed comprehensive medical center in western Florida to enhance blood volume analysis capabilities [1][2] - The ezBVA Lab service offers rapid 24-hour testing, aimed at optimizing heart failure treatment outcomes and reducing associated costs [1][2] - Daxor's BVA diagnostic provides 98% accurate data for individualized fluid management, which is crucial for improving patient outcomes in heart failure care [3] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with the BVA-100™ being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - The company is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, I am pleased to present our mid-year update for our unaudited first half results of 2024, highlighting Daxor Corporation's remarkable progress and financial performance. Our commitment to innovation in blood volume ana ...

Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 26th Annual Global Investment Conference being held on September 9-11, 2024 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning September 9, 2024 at 7:00 AM ET. Investors who wish to listen to the Company's presentation ca ...

Community Hospital Purchases BVA Analyzer With Focus on Improving Outpatient Heart Failure Care Oak Ridge, TN, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology through the acquisition of the BVA analyzer. This advancement not only enhances revenue streams, but also sets the stage for projected accelerated sales growth for the rest of the year. A rural 339-bed comm ...

Oak Ridge, TN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it has been awarded a $1.9M two-year contract from the U.S. Air Force (USAF) to support the continued development of a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer for military and civilian applications. Michael Feldschuh, Daxor's President and CEO, highlighted the significance of this ...

Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) services with the launch of the ezBVA lab service in three new facilities, anticipating sustained accelerated sales growth for the remainder of the year [1][3] Company Developments - Recent sales achievements include the adoption of Daxor's ezBVA Lab service by a leading full-service medical center in Georgia, a purchase by a hospital in North Carolina that is part of the largest non-profit health system, and implementation by a top-rated hospital in Central Florida [2] - The ezBVA lab service is a CLIA certified facility that provides next-day blood volume analysis results, enhancing patient care while managing healthcare expenses [3] Technology and Impact - Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition, with over 65,000 tests performed across leading U.S. hospital centers [4] - The technology has shown significant benefits in reducing mortality and readmissions in heart failure and critical care patients, indicating its critical role in fluid management [4]

The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA) Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matchingfund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminate ...

Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market Penetration Recent sales wins include: "Our unwavering focus on expanding market presence continues to yield strong results. The strategic investments we've made in our sales and marketing efforts are clearly bearing fruit," stated Michael Feldschuh, CEO and President of Daxor. "This growth underscores the increasing recognition of our blood volume analysis technology as a critical tool in improving patient outcomes." Daxor Corporation ...

Core Insights - Daxor Corporation is a leader in blood volume measurement technology, showcasing its innovative BVA technology at the AAHFN Annual Meeting, emphasizing its potential to improve heart failure management and overall cardiovascular care [1][2] - The BVA-100® is the only FDA-cleared diagnostic blood test for accurate blood volume status and composition, with over 65,000 tests performed, significantly reducing mortality and readmissions in heart failure and critical care [1] - Daxor is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [1] Event Participation - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, in Orlando, Florida, aimed at advancing nursing education and improving heart failure patient outcomes [2]

Core Insights - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, showcasing its blood volume measurement technology [1][4] - The AAHFN is focused on improving heart failure patient outcomes through education, clinical practice, and research [1] - Daxor's BVA technology is positioned as a transformative tool in heart failure management, aiming to reduce hospital stays, 30-day readmissions, and mortality rates [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100® diagnostic test, which is FDA-cleared for accurate blood volume quantification [8] - Over 65,000 tests have been conducted in U.S. hospitals, contributing to improved performance metrics in various medical conditions, particularly in heart failure and critical care [8] - The company is engaged in ongoing trials for heart failure treatment with NIH support and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [8]